These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 12743148)

  • 21. Efficacy of a nitrogen-containing bisphosphonate, minodronate, in conjunction with a p38 mitogen activated protein kinase inhibitor or doxorubicin against malignant bone tumor cells.
    Kubo T; Shimose S; Matsuo T; Sakai A; Ochi M
    Cancer Chemother Pharmacol; 2008 Jun; 62(1):111-6. PubMed ID: 17874104
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Overexpression of papillomavirus binding factor in Ewing's sarcoma family of tumors conferring poor prognosis.
    Yabe H; Tsukahara T; Kawaguchi S; Wada T; Sato N; Morioka H; Yabe H
    Oncol Rep; 2008 Jan; 19(1):129-34. PubMed ID: 18097586
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Imatinib mesylate inhibits Leydig cell tumor growth: evidence for in vitro and in vivo activity.
    Basciani S; Brama M; Mariani S; De Luca G; Arizzi M; Vesci L; Pisano C; Dolci S; Spera G; Gnessi L
    Cancer Res; 2005 Mar; 65(5):1897-903. PubMed ID: 15753388
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a phase II clinical trial.
    Krug LM; Crapanzano JP; Azzoli CG; Miller VA; Rizvi N; Gomez J; Kris MG; Pizzo B; Tyson L; Dunne M; Heelan RT
    Cancer; 2005 May; 103(10):2128-31. PubMed ID: 15812822
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Kit and PDGFR-alpha activities are necessary for Notch4/Int3-induced tumorigenesis.
    Raafat A; Zoltan-Jones A; Strizzi L; Bargo S; Kimura K; Salomon D; Callahan R
    Oncogene; 2007 Feb; 26(5):662-72. PubMed ID: 16878155
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Insulin-like growth factor I receptor-mediated circuit in Ewing's sarcoma/peripheral neuroectodermal tumor: a possible therapeutic target.
    Scotlandi K; Benini S; Sarti M; Serra M; Lollini PL; Maurici D; Picci P; Manara MC; Baldini N
    Cancer Res; 1996 Oct; 56(20):4570-4. PubMed ID: 8840962
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth.
    Krystal GW; Honsawek S; Litz J; Buchdunger E
    Clin Cancer Res; 2000 Aug; 6(8):3319-26. PubMed ID: 10955819
    [TBL] [Abstract][Full Text] [Related]  

  • 28. c-Kit is preferentially expressed in MYCN-amplified neuroblastoma and its effect on cell proliferation is inhibited in vitro by STI-571.
    Vitali R; Cesi V; Nicotra MR; McDowell HP; Donfrancesco A; Mannarino O; Natali PG; Raschellà G; Dominici C
    Int J Cancer; 2003 Aug; 106(2):147-52. PubMed ID: 12800187
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Growth inhibition of rat osteosarcoma and malignant fibrous histiocytoma cells by tyrosine kinase inhibitor STI571.
    Yoshitani K; Honoki K; Morishita T; Kido A; Miyauchi Y; Mii Y; Takakura Y
    In Vivo; 2003; 17(3):255-8. PubMed ID: 12929576
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preclinical in vivo study of new insulin-like growth factor-I receptor--specific inhibitor in Ewing's sarcoma.
    Manara MC; Landuzzi L; Nanni P; Nicoletti G; Zambelli D; Lollini PL; Nanni C; Hofmann F; García-Echeverría C; Picci P; Scotlandi K
    Clin Cancer Res; 2007 Feb; 13(4):1322-30. PubMed ID: 17317844
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nucleophosmin as a candidate prognostic biomarker of Ewing's sarcoma revealed by proteomics.
    Kikuta K; Tochigi N; Shimoda T; Yabe H; Morioka H; Toyama Y; Hosono A; Beppu Y; Kawai A; Hirohashi S; Kondo T
    Clin Cancer Res; 2009 Apr; 15(8):2885-94. PubMed ID: 19351769
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Analysis of protein tyrosine kinases expression in the melanoma metastases of patients treated with Imatinib Mesylate (STI571, Gleevec).
    Ivan D; Niveiro M; Diwan AH; Eton O; Kim KB; Lacey C; Gonzalez C; Prieto VG
    J Cutan Pathol; 2006 Apr; 33(4):280-5. PubMed ID: 16630177
    [TBL] [Abstract][Full Text] [Related]  

  • 33. STI 571 inhibition effect on KITAsn822Lys-mediated signal transduction cascade.
    Beghini A; Bellini M; Magnani I; Colapietro P; Cairoli R; Morra E; Larizza L
    Exp Hematol; 2005 Jun; 33(6):682-8. PubMed ID: 15911092
    [TBL] [Abstract][Full Text] [Related]  

  • 34. AKT mediates the pro-survival effects of KIT in ovarian cancer cells and is a determinant of sensitivity to imatinib mesylate.
    Shaw TJ; Vanderhyden BC
    Gynecol Oncol; 2007 Apr; 105(1):122-31. PubMed ID: 17169414
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differential effect of imatinib and synergism of combination treatment with chemotherapeutic agents in malignant glioma cells.
    Ren H; Tan X; Dong Y; Giese A; Chou TC; Rainov N; Yang B
    Basic Clin Pharmacol Toxicol; 2009 Mar; 104(3):241-52. PubMed ID: 19159435
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Xg expression in Ewing's sarcoma is of prognostic value and contributes to tumor invasiveness.
    Meynet O; Scotlandi K; Pradelli E; Manara MC; Colombo MP; Schmid-Antomarchi H; Picci P; Bernard A; Bernard G
    Cancer Res; 2010 May; 70(9):3730-8. PubMed ID: 20388798
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression of imatinib mesylate-targeted kinases in endometrial carcinoma.
    Slomovitz BM; Broaddus RR; Schmandt R; Wu W; Oh JC; Ramondetta LM; Burke TW; Gershenson DM; Lu KH
    Gynecol Oncol; 2004 Oct; 95(1):32-6. PubMed ID: 15385107
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-beta in ovarian serous carcinoma and normal ovarian surface epithelium.
    Schmandt RE; Broaddus R; Lu KH; Shvartsman H; Thornton A; Malpica A; Sun C; Bodurka DC; Gershenson DM
    Cancer; 2003 Aug; 98(4):758-64. PubMed ID: 12910520
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In Ewing's sarcoma CCN3(NOV) inhibits proliferation while promoting migration and invasion of the same cell type.
    Benini S; Perbal B; Zambelli D; Colombo MP; Manara MC; Serra M; Parenza M; Martinez V; Picci P; Scotlandi K
    Oncogene; 2005 Jun; 24(27):4349-61. PubMed ID: 15824736
    [TBL] [Abstract][Full Text] [Related]  

  • 40. KIT/stem cell factor expression in premalignant and malignant lesions of the colon mucosa in relationship to disease progression and outcomes.
    Bellone G; Smirne C; Carbone A; Buffolino A; Scirelli T; Prati A; Solerio D; Pirisi M; Valente G; Nano M; Emanuelli G
    Int J Oncol; 2006 Oct; 29(4):851-9. PubMed ID: 16964380
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.